Published 11/06/2009 by Pharma Times
Biota/Daiichi Sankyo's flu drug in new Phase III trial
Biota Holdings of Australia and partner Daiichi Sankyo it has begun a late-stage trial in Japan for the preventative use of their investigational antiviral laninamivir for influenza.
Earlier this year the companies presented promising data Phase III Asian trials for the therapeutic use of laninamivir,...
Share this
There are no more reports on this story yet.